» Articles » PMID: 9335081

Influence of Clonidine on Psychopathological, Endocrine and Respiratory Effects of Cholecystokinin Tetrapeptide in Patients with Panic Disorder

Overview
Specialty Pharmacology
Date 1997 Oct 23
PMID 9335081
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The influence of clonidine pretreatment on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide (CCK-4) was characterized. Patients with panic disorder (DSM-III-R) were given 50 micrograms CCK-4 i.v. at 1100 hours on 2 separate study days. In a randomized double-blind design they were additionally infused with 150 micrograms clonidine or placebo from 1040 to 1110 hours. After CCK-4 all patients experienced symptom attacks. No effects of clonidine on panic psychopathology or blood gas parameters were observed. After CCK-4, in the clonidine condition the pituitary release of adrenocorticotropin (ACTH) and prolactin was seemingly enhanced compared to placebo. Our results suggest that CCK-4-induced panic attacks are not suppressible by presynaptic alpha-2 receptor stimulation. Moreover, they point to a synergistic postsynaptic action of clonidine to CCK-4 upon pituitary hormone secretion. The diverging sites of action might possibly explain the discrepancies of psychopathological alterations and stress hormone secretion.

Citing Articles

Gut-Brain Neuroendocrine Signaling Under Conditions of Stress-Focus on Food Intake-Regulatory Mediators.

Stengel A, Tache Y Front Endocrinol (Lausanne). 2018; 9:498.

PMID: 30210455 PMC: 6122076. DOI: 10.3389/fendo.2018.00498.


Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.

Bowers M, Ressler K Neuropsychopharmacology. 2014; 40(3):688-700.

PMID: 25176168 PMC: 4289957. DOI: 10.1038/npp.2014.225.


Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders.

Ming X, Mulvey M, Mohanty S, Patel V Adolesc Health Med Ther. 2014; 2:105-12.

PMID: 24600280 PMC: 3926778. DOI: 10.2147/AHMT.S15672.


Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.

Eser D, Schule C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M Psychopharmacology (Berl). 2007; 192(4):479-87.

PMID: 17318504 DOI: 10.1007/s00213-007-0738-7.


Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Zwanzger P, Rupprecht R J Psychiatry Neurosci. 2005; 30(3):167-75.

PMID: 15944741 PMC: 1089777.